March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for ...
Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to ...
CBD and CBG, two non-intoxicating cannabis compounds, may help combat fatty liver disease by boosting liver energy reserves ...
GSK has agreed to sell its worldwide rights to develop and commercialise its experimental liver disease drug ...
The British pharma giant will hand off its experimental itch treatment to Italian company Alfasigma as it focuses on broader ...
Alfasigma has agreed to buy the global rights to GSK’s experimental liver disease drug in a deal worth up to $690m.
Naturally occurring chemicals in cannabis have been shown to reduce cholesterol–and the risk of deadly fatty liver disease, ...
In experiments on pigs, researchers found that some formula fats can strain the newborn liver far earlier than expected.
News-Medical.Net on MSN
Women face higher liver fibrosis risk from cardiometabolic factors than men
Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors. The ...
By Dennis Thompson HealthDay ReporterMONDAY, March 2, 2026 (HealthDay News) — A new, easy-to-use blood test can identify when ...
GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...
Researchers have discovered that non-psychoactive cannabis compounds, CBD and CBG, can significantly reduce liver fat and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results